AbbVie announced the FDA’s approval of risankizumab-rzaa (Skyrizi) as the first specific interleukin-23 inhibitor for treatment of moderate to severe Crohn’s disease in adults.
Risankizumab showed significant improvement in clinical and endoscopic responses in two induction trials and one maintenance trial, according to a company release.